| Jude Sudario, DNP | |
|
300 Pasteur Dr, Stanford, CA 94305-2200 | |
| (650) 723-4000 | |
| Not Available |
| Full Name | Jude Sudario |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Experience | 11 Years |
| Location | 300 Pasteur Dr, Stanford, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023430014 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 95000175 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Stanford Health Care | Stanford, CA | Hospital |
| Stanford Health Care - Valleycare | Pleasanton, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Stanford Health Care | 6709797491 | 2572 |
News Archive
A Kids' Brain Tumor Cure Foundation, Solving Kids' Cancer and the Ty Louis Campbell Foundation announce their joint financial support of a Phase 1 clinical trial to test the safety and efficacy of combination checkpoint inhibitors in the treatment of children with brain tumors.
Slate: "One of the biggest lingering criticisms of the Democrats' health care reform plan is that it doesn't control costs. This line persists in part because it's hard to refute in simple terms. ... But for those who want a single, clear example of how reform will attempt to keep the cost of health care - or, at least, the cost of insurance - down, there's no easier-to-grasp concept than the medical loss ratio."
Goodwin Biotechnology, Inc., a biological Contract Development and Manufacturing Organization that specializes in bioprocess development and GMP manufacturing of biopharmaceuticals utilizing Mammalian Cell Culture expression systems and Bioconjugation technologies, was selected by Panacea Pharmaceuticals, Inc. to complete a novel Fill / Finish project, as well as Quality Control release and stability testing for a therapeutic, nanoparticle cancer vaccine based on the Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH) tumor-specific protein to support Phase I clinical trials in patients with various solid tumor cancers.
Omega Healthcare Investors, Inc. today announced its results of operations for the three- and twelve-month period ended December 31, 2012. The Company also reported Funds From Operations ("FFO") available to common stockholders for the three-month period ended December 31, 2012 of $61.4 million or $0.55 per common share.
› Verified 3 days ago
| Entity Name | Stanford Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437292927 PECOS PAC ID: 6709797491 Enrollment ID: O20031124000348 |
News Archive
A Kids' Brain Tumor Cure Foundation, Solving Kids' Cancer and the Ty Louis Campbell Foundation announce their joint financial support of a Phase 1 clinical trial to test the safety and efficacy of combination checkpoint inhibitors in the treatment of children with brain tumors.
Slate: "One of the biggest lingering criticisms of the Democrats' health care reform plan is that it doesn't control costs. This line persists in part because it's hard to refute in simple terms. ... But for those who want a single, clear example of how reform will attempt to keep the cost of health care - or, at least, the cost of insurance - down, there's no easier-to-grasp concept than the medical loss ratio."
Goodwin Biotechnology, Inc., a biological Contract Development and Manufacturing Organization that specializes in bioprocess development and GMP manufacturing of biopharmaceuticals utilizing Mammalian Cell Culture expression systems and Bioconjugation technologies, was selected by Panacea Pharmaceuticals, Inc. to complete a novel Fill / Finish project, as well as Quality Control release and stability testing for a therapeutic, nanoparticle cancer vaccine based on the Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH) tumor-specific protein to support Phase I clinical trials in patients with various solid tumor cancers.
Omega Healthcare Investors, Inc. today announced its results of operations for the three- and twelve-month period ended December 31, 2012. The Company also reported Funds From Operations ("FFO") available to common stockholders for the three-month period ended December 31, 2012 of $61.4 million or $0.55 per common share.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jude Sudario, DNP 300 Pasteur Dr, Stanford, CA 94305-2200 Ph: (650) 723-4000 | Jude Sudario, DNP 300 Pasteur Dr, Stanford, CA 94305-2200 Ph: (650) 723-4000 |
News Archive
A Kids' Brain Tumor Cure Foundation, Solving Kids' Cancer and the Ty Louis Campbell Foundation announce their joint financial support of a Phase 1 clinical trial to test the safety and efficacy of combination checkpoint inhibitors in the treatment of children with brain tumors.
Slate: "One of the biggest lingering criticisms of the Democrats' health care reform plan is that it doesn't control costs. This line persists in part because it's hard to refute in simple terms. ... But for those who want a single, clear example of how reform will attempt to keep the cost of health care - or, at least, the cost of insurance - down, there's no easier-to-grasp concept than the medical loss ratio."
Goodwin Biotechnology, Inc., a biological Contract Development and Manufacturing Organization that specializes in bioprocess development and GMP manufacturing of biopharmaceuticals utilizing Mammalian Cell Culture expression systems and Bioconjugation technologies, was selected by Panacea Pharmaceuticals, Inc. to complete a novel Fill / Finish project, as well as Quality Control release and stability testing for a therapeutic, nanoparticle cancer vaccine based on the Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH) tumor-specific protein to support Phase I clinical trials in patients with various solid tumor cancers.
Omega Healthcare Investors, Inc. today announced its results of operations for the three- and twelve-month period ended December 31, 2012. The Company also reported Funds From Operations ("FFO") available to common stockholders for the three-month period ended December 31, 2012 of $61.4 million or $0.55 per common share.
› Verified 3 days ago
Angie Dee Murkins, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Gloria Le Choi, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Mrs. Joi Mei Soucy, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Olinda Su Mar, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Laura Lynne Asaro, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 875 Blake Wilbur Dr, Clinic D, Stanford, CA 94305 Phone: 650-723-6197 | |
Nancy S. Brook, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-498-7103 | |
Mr. Richard Quitevis, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-724-2906 |